Overview

Safety and Efficacy of ARQ-252 Cream 0.3% in Subjects With Non-Segmental Facial Vitiligo

Status:
Terminated
Trial end date:
2021-08-09
Target enrollment:
Participant gender:
Summary
This study will assess the safety and efficacy of ARQ-252 cream in combination with NB-UVB phototherapy treatment in individuals with non-segmental facial vitiligo.
Phase:
Phase 2
Details
Lead Sponsor:
Arcutis Biotherapeutics, Inc.